Show some success in medicine and others will follow. Genentech's soon to be licensed T-DM1 for the treatment of breast cancer has spawned many other entrants pouring into the ADC field. The latest to play is Menarini.
Menarini today announced a partnering effort with Oxford BioTherapeutics on 5 new programs aimed at the development of ADC cancer therapeutics. Oxford will supply the antibody, linking technology and cancer targets. Menarini will do the manufacturing and development work. Both will pursue clinicals and commercialization in different parts of the world. Oxford gets North America and Japan, while Menarini takes Europe, Asia and Latin America.
The arrangment is expected to speed Oxford's participation in clinical trials and helps bolster Menarini's pipeline. Both should benefit if the therapies succeed. See Fierce Biotech.
Posted by Bruce Lehr Oct 29th 2012.